EBITDA came in at ₹391.5 crore, down 2.6% from ₹402 crore a year ago, and significantly below the expected ₹499 crore. The operating margin stood at 12.45%, lower than 13.69% in the same period last year and well below the street estimate of 16%.
CEO Vikas Gupta said the company ended the year on a strong note. “Our domestic business continues to gain momentum, reinforcing our confidence in its long-term growth trajectory,” he said, highlighting strong execution and targeted initiatives.
In the India market, Alkem registered 6.5% YoY growth in Q4, slightly trailing the broader Indian Pharmaceutical Market’s 6.9%. However, its acute segment outpaced the market, growing 7.5%, or 150 basis points ahead of the IPM.
International business sales grew 7.2% YoY. The US contributed 19.6% to total sales, down from 21.6% a year ago, while non-US international markets rose to an 11.8% share from 9.9% in Q4 FY24.
During the quarter, Alkem filed six ANDAs and received four approvals from the USFDA.
Also Read: Samvardhana Motherson Q4 Results: Operational performance weak as margin narrows from last year
The company recommended a final dividend of ₹8 per equity share and scheduled its AGM for 25 August 2025, with the record date fixed as 8 August. The dividend, if approved, will be paid from 29 August.
Shares of Alkem Laboratories were trading at ₹5,165.00 on the BSE, down 1.91% as of 2:36 PM.
